Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluationCompelling anti-inflammatory activity of G1090N was ...

Newron Pharmaceuticals further expands its intellectual property portfolio for Evenamide with a new EU composition of matter ...

Plants mobilize their immune defenses far earlier than scientists have believed for decades—and through a previously ...

The Ilocos Norte provincial government is migrating to a new digital communication system, which may cause intermittent ...